HEALTH CARE
- Share via
Medco to Pay $51.5 Million in Stock for Repligen: Medco Research Inc. said the deal will give it several new products in early stages of human testing. The Research Triangle Park, N.C.-based company said it will issue new stock to be exchanged for Repligen Corp. shares, warrants and outstanding employee options. The deal is a boost to troubled Cambridge, Mass.-based Repligen, which has been cutting staff in an effort to continue its research and development program, and it would give Medco a new product portfolio in the cardiovascular, cancer and immunology markets.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
